Can a patient use a spacer with Anoro Ellipta (umeclidinium/vilanterol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, a spacer cannot be used with Anoro Ellipta

Anoro Ellipta is a dry powder inhaler (DPI) that is incompatible with spacer devices. Spacers are specifically designed for use with pressurized metered-dose inhalers (pMDIs), not dry powder inhalers 1.

Why Spacers Don't Work with Anoro Ellipta

The Ellipta device delivers medication through a fundamentally different mechanism than pMDIs:

  • DPIs require rapid, forceful inhalation (approximately 60 L/min) to disperse the powder from the blister strips and deliver the medication to the lungs 2, 1
  • Spacers work with pMDIs that use propellant to aerosolize medication, where the spacer acts as a holding chamber to reduce the need for hand-breath coordination 2
  • The Ellipta device contains two foil blister strips with powder that must be activated by the patient's inspiratory flow—adding a spacer would completely disrupt this mechanism 1

Device-Specific Technique for Anoro Ellipta

The FDA label clearly describes that Anoro Ellipta:

  • Delivers 55 mcg umeclidinium and 22 mcg vilanterol when tested at 60 L/min flow rate 1
  • Requires the patient to inhale directly through the mouthpiece to create the airstream that disperses the powder 1
  • Studies show patients with severe COPD achieve mean peak inspiratory flows of 66.5 L/min through the Ellipta device (range 43.5-81.0 L/min), which is adequate for drug delivery 1

Common Pitfall to Avoid

Do not attempt to attach any spacer or valved holding chamber to the Ellipta inhaler. The guidelines explicitly state that breath-actuated MDIs "cannot be used with currently available spacer/VHC devices" 2, and this applies even more critically to DPIs like the Ellipta, which have a completely different delivery mechanism requiring direct inhalation through the device.

If a patient cannot generate adequate inspiratory flow for a DPI, consider switching to a pMDI with spacer or nebulizer rather than attempting to modify the Ellipta device 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.